- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05137899
Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy (ADVANCE HCC)
Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy Prior to Hepatectomy in Hepatocellular Carcinoma With Portal Vein Tumour Thrombus (ADVANCE HCC) Hoffmann La Roche Protocol Number: ML42525
Study Overview
Status
Intervention / Treatment
Detailed Description
Surgical resection without adjuvant therapy is the standard of care for most patients with solitary hepatocellular carcinoma (HCC). The presence of portal vein tumour thrombus (PVTT) is associated with a poor prognosis, and as a result patients usually do not undergo surgery.1 One potential strategy to improve the outcome of patients with HCC and PVTT is to administer treatment to the tumour prior to surgery, i.e. "neoadjuvant" therapy. This strategy has been proven to be effective in other types of cancer, and results in tumour downstaging and potentially eliminates micro-metastatic disease In a recent randomized controlled trial (RCT) in patients with HCC and PVTT, the addition of radiation therapy (RT) to the tumour prior to hepatic surgery was compared with surgery alone.4 There was a statistically significant improvement in survival with RT. Systemic therapy with the tyrosine kinase inhibitor Sorafenib improved survival compared to placebo in patients with advanced HCC and PVTT.5 Another recent trial in patients with advanced HCC demonstrated improved survival with the combination of Atezolizumab, an immune checkpoint inhibitor (ICI), and Bevacizumab, an antibody to vascular endothelial growth factor compared to Sorafenib alone.6
Currently, there is no standard of care for the neoadjuvant treatment of solitary HCC. Radiotherapy has not been widely adopted despite recent evidence suggesting some benefit. It is conceivable that RT will downsize the tumour increasing the surgical resection rate and reducing the shedding of tumour cells. Stereotactic Body Radiation Therapy (SBRT) is a type of RT that provides high dose, focal radiation to tumours using highly precise imaging and treatment fields, with rapid dose fall-off thereby sparing normal tissue. Based on experience in other cancers, it would seem judicious that effective systemic therapy be considered for the neoadjuvant treatment of HCC to downsize the primary tumour and eradicate occult micro-metastases.2,3
We hypothesize that treating patients with HCC and PVTT with either 1) neoadjuvant systemic therapy, or 2) neoadjuvant SBRT may lead to improved hepatic resection rates. Complete hepatic resection is being considered as a surrogate for good long-term outcomes. The aim of our randomized Phase II trial is to select the treatment arm with the most favourable outcomes based on a trade-off between resection rate and toxicity for study in a future trial.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Erin McGean
- Phone Number: 4256 905-527-2299
- Email: mcgeane@mcmaster.ca
Study Contact Backup
- Name: Lisa Rudd-Scott, RN BScN MN
- Phone Number: 43793 905-527-2299
- Email: ruddl@mcmaster.ca
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada
- Recruiting
- Tom Baker Cancer Centre
-
Contact:
- Vincent Tam, MD
- Email: vincent.tam@albertahealthservices.ca
-
Edmonton, Alberta, Canada
- Not yet recruiting
- Cross Cancer Institute
-
Contact:
- Hatim Karachiwala, MD
- Email: hatim.karachiwala@albertahealthservices.ca
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V5C2
- Recruiting
- Juravinski Cancer Centre
-
Contact:
- Brandon Meyers, MD
- Phone Number: 64609 905-521-2100
- Email: meyersbr@hhsc.ca
-
Ottawa, Ontario, Canada, K1H8L6
- Recruiting
- Ottawa Regional Cancer Centre
-
Contact:
- Guillaume Martel, MD
- Phone Number: 613-737-3518
- Email: gumartel@toh.ca
-
Contact:
- Kendra Christink
- Email: kchristink@toh.ca
-
Toronto, Ontario, Canada
- Not yet recruiting
- Princess Margaret Cancer Centre
-
Contact:
- Jennifer Knox, MD
- Email: jennifer.knox@uhn.ca
-
-
Quebec
-
Montreal, Quebec, Canada
- Not yet recruiting
- 8. Centre the recherche du Centre hospitalier de l'Université de Montréal - CHUM
-
Contact:
- Simon Turcotte, MD
- Email: simon.turcotte.med@ssss.gouv.qc.ca
-
Montréal, Quebec, Canada
- Not yet recruiting
- McGill Cedars Cancer Centre
-
Contact:
- Jamil Asselah, MD
- Email: jamil.asselah@mcgill.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Biopsy proven solitary HCC without biliary invasion, or metastases,
- PVTT involving the portal vein branches: Vp1-Vp3 (Japanese Classification for HCC with PVTT, see Appendix II),
- <10 cm maximal diameter on CT or MRI,
- Child-Pugh Class A (see Appendix III), within 14 days prior to randomization. (All parameters without transfusion within 3 months).
- Age > 18 years.
Exclusion Criteria:
Abnormal laboratory parameters (within 14 days of randomization):
- Hemoglobin < 90 g/L
- Platelet count < 75 x 109/L without transfusion
- INR >1.25
- Serum creatinine > 1.5 x ULN
- Urine dipstick for proteinuria > 2 (unless a 24-hour urine collection demonstrates < 1.5 g of protein in 24 hours.
Previous therapy for HCC:
- Systemic therapy, surgery or radiation therapy,
- Local therapy to the liver (e.g., ablation or embolization) within 28 days prior to randomization.
- ECOG performance status > 2 (see Appendix IV).
- Non-healing wound, skin ulcers, or incompletely healed bone fracture.
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to planned start of study therapy.
- History of bleeding from esophageal and/or gastric varices or high risk of bleeding from varices seen on endoscopy (normal EGD required within 6 months of randomization).
- History of GI perforation, abdominal fistulae, or intra-abdominal abscess.
Significant cardiovascular disease:
- New York Heart Association cardiac disease (Class II or greater),
- Myocardial infarction, unstable angina or cerebrovascular accident within past 3 months,
- Unstable arrhythmia,
- Poorly controlled arterial hypertension (defined as systolic blood pressure (BP) > 150 mmHg and/or diastolic blood pressure > 100 mmHg) based on an average of > 3 BP readings on > 2 sessions), or prior history of hypertensive crisis or hypertensive encephalopathy,
- Aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis within 6 months prior to randomization
- Known contraindication to Bevacizumab or Immune Checkpoint Inhibitor (ICI): Active or history of autoimmune disease or immune deficiency, including, but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis, autoimmune hypophysitis, or autoimmune pancreatitis. Includes known hypersensitivity to any component of Bevacizumab; Chinese hamster ovary cell products or other recombinant human or humanized antibodies. Known hypersensitivity to Atezolizumab or any of the excipients. (Note: Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone and those with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study).
- Known history of (Human immunodeficiency virus (HIV), HBV and HCV co-infection). For patients with active HBV: HBV DNA <500IU/mL obtained within 28 days prior to randomization and anti-HBV treatment (per local standard of care, e.g., entecavir) for a minimum of 14 days prior to study entry and willingness to continue treatment for the length of the study.
- Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia.
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis.
- Active tuberculosis.
- Prior allogeneic stem cell or solid organ transplantation.
- Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 [IL-2]) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment.
- Recent administration of live vaccine.
- History of malignancy other than HCC within 5 years prior to screening, with the exception of adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ of breast, or Stage I uterine cancer.
- Treatment with strong CYP3A4 inducers within 14 days prior to randomization.
- Treatment with an immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-α agents) within 14 days prior to randomization, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions: a) patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy), or b) patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency.
- Current or recent (within 7 days of randomization) use of aspirin (325mg/day), dipyramidole, ticlopidine, clopidogrel, or cilostazol, Vitamin K antagonists, direct oral anticoagulants (DOACs), LMWH.
- Recent history (within 4 weeks) of hemoptysis.
- History of TIA, CVA, or any arterial thrombotic event within 12 months before randomization.
- Sensory/motor neuropathy greater than or equal to grade 2, as defined by the NCI CTCAE and history of hypomagnesemia.
- Known severe allergic reaction to contrast (e.g., anaphylaxis).
- Pregnancy or lactating women.
- Inability to provide informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Neoadjuvant Atezolizumab/Bevacizumab
• Arm 1: neoadjuvant atezolizumab 1200 mg IV q3weeks x 4 cycles, and bevacizumab 15 mg/kg IV q3weeks x 4 cycles
|
Neoadjuvant atezolizumab/bevacizumab or neoadjuvant SBRT prior to hepatectomy
|
Experimental: Neoadjuvant SBRT
• Arm 2: neoadjuvant stereotactic body radiation therapy (SBRT), target volume 30 40 Gy, in 6-8 Gy per day over five days, delivered every other day
|
Neoadjuvant atezolizumab/bevacizumab or neoadjuvant SBRT prior to hepatectomy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hepatectomy
Time Frame: 17 Weeks
|
Proportion of patients who undergo hepatectomy in each arm (number of patients who undergo hepatectomy divided by the number of patients randomized to each arm).
|
17 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rate
Time Frame: 2 years
|
Radiological and pathological response rate to neoadjuvant therapy.
|
2 years
|
Toxicity to SBRT
Time Frame: 2 years
|
Toxicity rate related to neoadjuvant SBRT.
|
2 years
|
Postoperative complications
Time Frame: 90 days post operatively
|
Postoperative complication rate and mortality
|
90 days post operatively
|
Survival Progression Free
Time Frame: 2 years
|
Progression free survival (PFS).
|
2 years
|
Survival
Time Frame: 2 years
|
Overall survival (OS).
|
2 years
|
Toxicity to Atezolizumab/Bevacizumab
Time Frame: 2 years
|
Toxicity to Atezolizumab/Bevacizumab in the neoadjuvant setting
|
2 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Brandon Meyers, MD, principle investigator
- Study Director: Jim Wright, MD, OCOG Director
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Embolism and Thrombosis
- Liver Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Thrombosis
Other Study ID Numbers
- OCOG-2021-ADVANCE HCC ML42545
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
-
Edward KimBristol-Myers Squibb; National Cancer Institute (NCI)TerminatedUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
Clinical Trials on Neoadjuvant
-
Jiangsu Cancer Institute & HospitalRecruitingLocally Advanced Esophageal CarcinomaChina
-
Peking University First HospitalNot yet recruitingUrothelial Carcinoma of the Renal Pelvis and UreterChina
-
Chinese Academy of SciencesXiangya Hospital of Central South University; Peking University People's Hospital and other collaboratorsRecruitingGastric Cancer | Image | PathologyChina, Italy
-
Beijing Shijitan Hospital, Capital Medical UniversityRecruiting
-
Cancer Institute and Hospital, Chinese Academy...Recruiting
-
Lawson Health Research InstituteRecruitingLocally Advanced Breast Cancer | High-Risk CancerCanada
-
Azienda Ospedaliero-Universitaria CareggiRecruitingEarly Breast CancerItaly
-
Rachel MillerCompletedFallopian Tube Carcinoma | Ovarian Carcinoma | Primary Peritoneal CarcinomaUnited States
-
Peking University Cancer Hospital & InstituteUnknownQOL; Quality of Life;Gastric Cancer; Gastrectomy;Neoadjuvant ChemotherapyChina
-
Second Affiliated Hospital, School of Medicine,...Leiden University Medical CenterNot yet recruiting